BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CeNeS Pharmaceuticals PLC (CEN.L): Annual General Meeting (AGM) Statement


10/19/2005 5:09:25 PM

Cambridge, UK, 5 July 2005 -CeNeS announces that all resolutions put to Shareholders at today’s AGM were passed.

At the AGM CeNeS’ Chairman Alan Goodman said: In the last nine months CeNeS has delivered two successful clinical trial results, the first being a Phase III trial of our lead programme M6G for post-operative pain, that demonstrated its efficacy as an analgesic. The second successful result was in a Phase II proof of concept study of CNS 5161 in neuropathic pain. These results are evidence of the expertise of our clinical development team and their ability to design and implement clinical programmes. We look forward with confidence to progressing both these compounds to the next stages of their clinical development and also moving CNS 7056X, our novel short acting sedative, into the clinic in 2006.

Our earlier stage programme developing novel COMT (catechol-o-methyl transferase) inhibitors is also progressing well. The market for COMT inhibitors may expand substantially as the role of COMT is better understood in schizophrenia and other cognitive disorders in addition to the established market for the treatment of Parkinson’s disease.

I firmly believe CeNeS is well positioned to deliver value to its shareholders by further developing its balanced portfolio focused on improved treatments for disorders of the central nervous system and pain. CeNeS is looking forward with confidence to reaching important milestones in each of its programmes in the next 12 to 18 months.

For more information please contact:

CeNeS Pharmaceuticals plc Neil Clark

Tel: +44 (0)1223 266466

Northbank Communications

Emma Palmer

Douglas Pretsell

Rowan Minnion

Tel: +44 (0)20 7886 8150

About CeNeS Pharmaceuticals

CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson’s disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com.

London, W1W 5BB, UK



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES